Needham Upgrades Biogen to Buy, Announces $255 Price Target

Benzinga Newsdesk www.benzinga.com Positive 58.8%

Neg 0% Neu 0% Pos 58.8%

Needham analyst Ami Fadia upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $255 price target.

Comments

No comments yet. Be the first!